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Aims. Compare the effects of montelukast or dexamethasone in distal lung parenchyma and airway walls of guinea pigs (GP)
with chronic allergic inflammation.Methods. GP have inhaled ovalbumin (OVA group-2x/week/4weeks). After the 4th inhalation,
GP were treated with montelukast or dexamethasone. After 72 hours of the 7th inhalation, GP were anesthetised, and lungs
were removed and submitted to histopathological evaluation. Results. Montelukast and dexamethasone treatments reduced the
number of eosinophils in airway wall and distal lung parenchyma compared to OVA group (𝑃 < 0.05). On distal parenchyma,
both treatments were effective in reducing RANTES, NF-𝜅B, and fibronectin positive cells compared to OVA group (𝑃 < 0.001).
Montelukast was more effective in reducing eotaxin positive cells on distal parenchyma compared to dexamethasone treatment
(𝑃 < 0.001), while there was a more expressive reduction of IGF-I positive cells in OVA-D group (𝑃 < 0.001). On airway walls,
montelukast and dexamethasone were effective in reducing IGF-I, RANTES, and fibronectin positive cells compared to OVA group
(𝑃 < 0.05). Dexamethasone was more effective in reducing the number of eotaxin and NF-𝜅B positive cells than Montelukast
(𝑃 < 0.05). Conclusions. In this animal model, both treatments were effective in modulating allergic inflammation and remodeling
distal lung parenchyma and airway wall, contributing to a better control of the inflammatory response.
1. Introduction
Asthma plays an important role as a major cause of mortality
andmorbidity all over the world. Data from theWorldHealth
Organization estimates that 100 millions to 150 millions
people worldwide have a diagnosis of asthma [1], and around
180.000 people around the world die, every year, from
this disease. Moreover, asthma affects people in school age
and economically active people, having a high social and
economic impact with lost productivity and reduced partici-
pation in family life.Therefore, it is considered a public health
problem with high cost medications and hospitalizations of
patients, enhancing the importance of continuing studying
asthma.
Bronchial asthma is a chronic inflammatory disorder
involving chronic airway inflammation, tissue remodeling,
and declined airway function. The asthma physiopathology
involves mediators and many cells, mainly eosinophils which
plays important role through the release of specific mediators
[2], and the degree of eosinophilia has been related with the
disease severity in some asthmatic patients [3].
Eosinophil recruitment at the airway tissue is considered
a multifaceted mechanism which involves chemokines such
as eotaxins andRANTES. Besides that, a wide array of growth
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factors can be involved in airway inflammation, including
insulin-like growth factor-1 (IGF-I) which is upregulated dur-
ing this event [4], contributing with the remodeling process
[5]. Furthermore, we may also consider the extracellular
matrix (ECM) proteins, as fibronectin for example. Increased
deposition of fibronectin and collagen into the subepithelial
space of the airways is observed in all forms of asthma and
appears very early in the disease [6].
Much of the subjacent inflammation of asthma can
be mediated by the transcription nuclear factor-kappa B
(NF-𝜅B), which is involved in the regulation of many of
the inflammatory proteins that are expressed in asthmatic
airways [7].
The importance of distal lung responses to the global
pulmonary alterations enhancing asthma symptoms, partic-
ularly on severe asthma, has been recently addressed [8–10].
The inflammation process in the peripheral airways has a
highaffinity to cysteinyl leukotriene-1 receptors (CysLT
1
Rs),
and it is known that inhaled therapies are insufficient to
achieve the small airways [11]. It is also important to highlight
that important features of remodeling seem to occur mainly
in the small airways [12], emphasizing the importance of
targeting peripheral inflammation to achieve the disease
control.
Our group had previously shown that in the ovalbumin-
induced guinea pig asthmamodel, repeated allergen exposure
leads to chronic allergic airway and distal lung parenchyma
inflammation, characterized by an influx of eosinophils,
mast cells, and allergen-specific T cells, a Th2-type cytokine
pattern and airway and tissue remodeling [8, 13, 14].
Corticosteroids are the first-line therapy to threat asthma
patients and were considered the most important drugs to
improve hyperreactivity and bronchial hyperresponsiveness.
However, antileukotrienes may also be considered to control
asthma patients since cysteinyl leukotrienes (CysLTs) have
been known to play an important role in bronchoconstric-
tion and airway inflammation. CysLTs are synthesized from
arachidonic acid andmost of their actions aremediated by the
CysLT
1
Rs, a G protein-coupled receptor. CysLTs have many
pulmonary actions, including human airway smooth muscle
contraction, chemotaxis, mucous secretion, smooth muscle
proliferation, and increase in vascular permeability [15–18].
Clinical trials with anti-leukotriene drugs in mild and
moderate persistent asthmatics have shown improvement
in pulmonary function, symptoms, and need for rescue
medications and a reduction in asthma exacerbations [19,
20]. It has also been shown that antileukotrienes reduce
sputum and mucosal eosinophils in subjects with asthma
[21]. However, recent long duration trials have evaluated the
impact of antileukotrienes in comparison to glucocorticoids
and showed that symptoms, spirometry, 𝛽
2
-agonist use, and
also quality of life were improved to a greater extent with
glucocorticoids [22, 23].
Using the same experimental model described in the
present study, we observed that both montelukast or dexam-
ethasone treatments diminished collagen fiber content, met-
allopeptidase inhibitor-1 (TIMP-1), matrix metallopeptidase-
9 (MMP-9) and transforming growth factor (TGF-𝛽) in distal
lung parenchyma. Nonetheless, concerning elastic fiber con-
tent, dexamethasone’s treatment did not reduce this response
[24]. These foundings are in agreement with the results
observed by Goleva et al. [25], in the evaluation of asthmatic
patients resistant or not to corticosteroids.
Concerning these aspects, we considered pertinent to
evaluate the effects of corticosteroids (dexamethasone) and
antileukotrienes (montelukast sodium) in the eosinophilic
inflammation and remodeling process modulated by
fibronectin and IGF-I in an animal model of chronic allergic
inflammation, studying both compartments, airway walls,
and distal lung parenchyma.
2. Material and Methods
Guinea pigs (GP) were maintained in an animal facility with
a 12-hour light/dark cycle and fed water and chow ad libitum.
GP received humane care in compliance with the “Guide for
care and use of laboratory animals” [26], and all experiments
described in this study were previously approved by the
Institutional ReviewBoard of theUniversity of Sa˜o Paulo (Sa˜o
Paulo, Brazil/CAPpesq number 0276/09).
2.1. Experimental Groups. Four groups of GP were studied:
(a) saline group (SAL, 𝑛 = 8); (b) ovalbumin-sensitized GP
(OVA, 𝑛 = 8); (c) ovalbumin-sensitized GP treated with
montelukast (OVA-M, 𝑛 = 8); (d) ovalbumin-sensitized GP
treated with dexamethasone (OVA-D, 𝑛 = 8).
2.2. Induction of Chronic Pulmonary Allergic Inflammation.
Male Hartley GP, weighing 300–400 g, were placed in a plexi-
glass box (30 × 15 × 20 cm) coupled to an ultrasonic nebulizer
(Soniclear, Sa˜o Paulo, Brazil). A solution of ovalbumin (OVA,
Grade V, SigmaChemical Co., Saint Louis,MO,USA) diluted
in 0.9% NaCl (sterile saline solution) was prepared. The
animals received seven inhalations during four weeks with
increasing concentrations of OVA (1∼5mg/mL) in order to
avoid tolerance. Control animals received aerosolized normal
saline. The solution was continuously aerosolized into the
environment until respiratory distress occurred, or until 15
minutes had elapsed, as previously described [13, 14, 27]. The
observer who made the decision to withdraw the guinea pig
from the inhalation box was blinded to the treatment status
of the animal.
2.3. Montelukast and Dexamethasone Treatments. In order to
avoid interference with sensitization, only after twenty-four
hours of the fourth inhalation guinea pigs started to receive
either daily oral montelukast sodium 10mg⋅kg−1 (four hours
before inhalations of ovalbumin and at the same hour on the
other days) or dexamethasone (5mg⋅kg−1/day i.p.) [13, 28].
2.4. Morphometric Studies. After 4 weeks, guinea pigs were
anesthetized with sodium pentobarbital (50mg/kg intraperi-
toneally), tracheostomized, and ventilated at 60 breaths/min
(Harvard Apparatus South Natick, MA). Ten minutes after
OVA challenge, a positive end-expiratory pressure of 5 cm
H
2
O was applied to the respiratory system, and the airways
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were occluded at the end of expiration. GP were exsan-
guinated via the abdominal aorta, and lungs were removed
en bloc.
Lungs were fixed with buffered 4% formaldehyde. Sec-
tions representing peripheral areas were processed for paraf-
fin embedding. Histological sections of 3–5𝜇m in thickness
were stained and evaluated by persons blinded to the protocol
design. Morphometric analysis was performed with a light
microscope (Nikon, E200, City, Japan), with an integrating
eyepiece (composed of 100 points and 50 lines) using a point-
counting technique [13, 14, 29].
Three to five airways randomly selected from each lung
slide were focused at a magnification of ×1,000. The number
of eosinophils and positive cells for IGF-I, eotaxin, RANTES,
fibronectin, andNF-𝜅Bwas determined as numbers of points
of the integrating eyepiece falling on areas of cells or positive
cells in three randomly selected areas of each airway wall
divided by the number pointing in the airway wall area
(104 𝜇m2) [13, 14, 29].
To measure the number of positive cells in distal lung
parenchyma, we counted in 10 fields per slide the number of
eosinophils and positive cells for IGF-I, eotaxin, RANTES,
fibronectin, and NF-𝜅B in each field divided by alveolar
tissue area. Measurements were expressed as cells/104 𝜇m2,
at ×1,000 magnification (104 𝜇m2), divided by the number
pointing in the parenchyma area (104 𝜇m2) [29, 30].
2.5. Measurement of Eosinophil Density. Five𝜇m thick slides
of lung were stained with Luna [13, 31]. We analyzed the
density of eosinophils within the alveolar septa and in airway
walls as described above. Measurements were expressed as
cells/104 𝜇m2.
2.6. Immunohistochemistry. Immunohistochemistry was
performed with anti-IGF-I (1:75; Santa Cruz—Sc 9013), anti-
NF-𝜅B (1:50; Santa Cruz—Sc 109), anti-fibronectin (1:400;
DAKO 0245), anti-eotaxin (1:100; Santa Cruz—Sc 6181), and
anti-RANTES (1:400; Santa Cruz—Sc 1410) antibodies, by
peroxidase method [24, 29].
Using a 100-point grid (area: 104 𝜇m2at ×1,000 magnifi-
cation), the number of the positive cells for IGF-I, eotaxin,
RANTES, fibronectin, and NF-𝜅B was counted as mentioned
above in Section 2.4.
2.7. Data Analysis. Values are expressed as mean ± standard
error (SEM). Statistical analysis was performed using Sig-
maStat software (SPSS Inc, Chicago, IL, USA). Data were
evaluated by one-way analysis of variance (ANOVA) and
multiple comparisons were made usingHolm-Sidakmethod.
The P value < 0.05 was considered significant [32].
3. Results
3.1.Measurements of Eosinophils Density. Figure 1(a) presents
the mean and SEM values of eosinophilic recruitment in
distal lung parenchyma. We observed a significant increase
in the number of eosinophils (cells/104 𝜇m2) in OVA group
(9.91 ± 0.70) compared to control (SAL group: 2.62 ± 0.26).
There was a decrease of eosinophils in OVA-M (3.03 ± 0.28)
and OVA-D (4.17±0.36) compared to OVA(𝑃 < 0.05).There
were no significant differences between OVA-M group and
OVA-D group.
Figure 1(b) presents the mean and SEM values of
eosinophilic recruitment in airway walls. We observed a sig-
nificant increase in the number of eosinophils (cells/104 𝜇m2)
inOVA group (17.72±3.79) compared to control (SAL group:
4.89 ± 0.97). There was a decrease of eosinophils in OVA-M
(11.55±0.87) andOVA-D (8.05±0.67) compared toOVA(𝑃 <
0.05). There were no significant differences between OVA-M
group and OVA-D group.
3.2. Measurements of Eotaxin Expression. Considering
eotaxin expression in inflammatory cells (Figure 2(a)), we
observed a significant increase in the number of eotaxin
positive cells (104 𝜇m2) in distal lung parenchyma in OVA
group (19.38 ± 0.79) compared to control (SAL group:
3.00 ± 0.39, 𝑃 < 0.001). There was a decrease of eotaxin
positive cells in OVA-M (5.65±0.38) and OVA-D (9.9±0.54)
compared to OVA(𝑃 < 0.001). There was a significant
reduction of eotaxin positive cells in OVA-M compared to
OVA-D (𝑃 < 0.001).
Figure 2(b) shows eotaxin expression in inflammatory
cells in airway walls.We observed a significant increase in the
number of eotaxin positive cells (104 𝜇m2) on airway walls in
OVA group (13.23 ± 1.18) compared to control (SAL group:
6.92 ± 0.99, 𝑃 < 0.001). There was a significant decrease of
eotaxin positive cells in OVA-M (9.29 ± 0.86) and in OVA-D
(7.03 ± 0.70) compared to OVA (𝑃 < 0.001). There were no
differences between OVA-D and OVA-M groups.
3.3. Measurements of RANTES Expression. The RANTES
expression in distal lung parenchyma is shown in Figure 3(a).
There was a significant increase in RANTES expression (pos-
itive cells/104 𝜇m2) in OVA group (19.84 ± 1.25) compared
to control (SAL group: 2.40 ± 0.35, 𝑃 < 0.001). There was
a significant decrease of RANTES positive cells in OVA-M
(6.44 ± 0.66) and in OVA-D (5.47 ± 0.54) compared to OVA
(𝑃 < 0.001). There were no differences between OVA-D and
OVA-M groups.
Figure 3(b) shows RANTES expression in airway walls
(positive cells/104 𝜇m2). There was a significant increase in
RANTES expression in OVA group (27.56 ± 1.83) compared
to control (SAL group: 18.88 ± 1.31, 𝑃 < 0.05). There was
a significant decrease of RANTES positive cells in OVA-M
(18.14±1.30) and in OVA-D (20.05±1.24) compared to OVA
(𝑃 < 0.05). There were no differences between OVA-D and
OVA-M groups.
3.4. Measurements of IGF-I. Considering IGF-I expression in
inflammatory cells (Figure 4(a)), we observed a significant
increase in the number of IGF-I positive cells (104 𝜇m2)
in distal lung parenchyma in OVA group (22.89 ± 1.16)
compared to control (SAL group: 4.87 ± 0.93, 𝑃 < 0.001).
There was a decrease of IGF-I positive cells in OVA-M
(11.83 ± 0.51) and OVA-D (6.21 ± 0.56) compared to OVA
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Figure 1: (a) Mean and SEM values of eosinophil in distal lung of GP that previously inhaled normal saline or ovalbumin, and after the 4th
inhalation, GP were treated withmontelukast (OVA-M group) and dexamethasone (OVA-D group). ∗𝑃 < 0.05 compared to the other groups.
∗∗
𝑃 < 0.05 compared to SAL group. (b) Mean and SEM values of eosinophil in airway wall of GP that previously inhaled normal saline or
ovalbumin, and after the 4th inhalation, GP were treated with montelukast (OVA-M group) and dexamethasone (OVA-D group). ∗𝑃 < 0.05
compared to the other groups. ∗∗𝑃 < 0.05 compared to SAL group.
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Figure 2: (a) Mean and SEM values of eotaxin positive cells in distal lung of GP that previously inhaled normal saline or ovalbumin, and
after the 4th inhalation, GP were treated with montelukast (OVA-M group) and dexamethasone (OVA-D group). ∗𝑃 < 0.001 compared to
the other groups. ∗∗𝑃 < 0.001 compared to SAL and OVA-D groups. #𝑃 < 0.001 compared to SAL group. (b) Mean and SEM values of
Eotaxin positive cells in airway wall of GP that previously inhaled normal saline or ovalbumin, and after the 4th inhalation, GP were treated
with montelukast (OVA-M group) and dexamethasone (OVA-D group). ∗𝑃 < 0.001 compared to SAL, OVA-M and OVA-D groups.
(𝑃 < 0.001). There was a significant reduction of IGF-I
positive cells in OVA-D compared to OVA-M (𝑃 < 0.001).
There were no differences between OVA-D compared to SAL
group.
Figure 4(b) presents the mean and SEM values of IGF-
I positive cells (104 𝜇m2) in airway walls. We observed a
significant increase in expression of IGF-I positive cells in
OVA group (50.70 ± 1.43) compared to control (SAL group:
25.70 ± 1.79). There was a decrease of IGF-I positive cells in
OVA-M (25.53±1.36) andOVA-D (20.90±4.35) compared to
OVA (𝑃 < 0.001).There were no differences betweenOVA-M
and OVA-D groups.
3.5. Measurements of Fibronectin Positive Cells. Figure 5(a)
shows the number of fibronectin positive cells (104 𝜇m2) in
distal lung parenchyma. We observed a significant increase
in the number of fibronectin positive cells in OVA group
(25.25 ± 0.90) compared to control (SAL group: 8.61 ± 0.70,
𝑃 < 0.001).There was a significant decrease in the number of
fibronectin positive cells in OVA-M (13.41 ± 0.47) and OVA-
D (14.61 ± 0.82), compared to OVA group (𝑃 < 0.001). There
were no significant differences between OVA-D and OVA-M
groups.
Figure 5(b) shows the number of fibronectin positive cells
(104 𝜇m2) in airway walls. We observed a significant increase
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Figure 3: (a) Mean and SEM values of RANTES positive cells in distal lung of GP that previously inhaled normal saline or ovalbumin and
after the 4th inhalation GP were treated with montelukast (OVA-M group) and dexamethasone (OVA-D group). ∗𝑃 < 0.001 compared to the
other groups. ∗∗𝑃 < 0.001 compared to SAL group. (b) Mean and SEM values of RANTES positive cells in airway wall of GP that previously
inhaled normal saline or ovalbumin and after the 4th inhalation GP were treated with montelukast (OVA-M group) and dexamethasone
(OVA-D group). ∗𝑃 < 0.05 compared to the other groups.
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Figure 4: (a) Mean and SEM values of IGF-I positive cells in distal lung of GP that previously inhaled normal saline or ovalbumin, and
after the 4th inhalation GP were treated with montelukast (OVA-M group) and dexamethasone (OVA-D group). ∗𝑃 < 0.001 compared to
the other groups. ∗∗𝑃 < 0.001 compared to SAL and OVA-D groups. (b) Mean and SEM values of IGF-I positive cells in airway wall of GP
that previously inhaled normal saline or ovalbumin, and after the 4th inhalation, GP were treated with montelukast (OVA-M group) and
dexamethasone (OVA-D group). ∗𝑃 < 0.001 compared to the other groups.
in the number of fibronectin positive cells in OVA group
(33.69 ± 1.66) compared to control (SAL group: 10.35 ± 5.98,
𝑃 < 0.001).There was a significant decrease in the number of
fibronectin positive cells in OVA-M (5.21±2.47) and OVA-D
(10.88 ± 3.33) animals compared to OVA group (𝑃 < 0.001).
There were no significant differences between OVA-D and
OVA-M groups.
3.6. Measurements of NF-𝜅B. Figure 6(a) shows the NF-𝜅B
expression in distal parenchyma. We observed a significant
increase in the number of NF-𝜅B (positive cells/104 𝜇m2) in
OVA group (31.38 ± 5.21) compared to control (SAL group:
5.38 ± 0.79, 𝑃 < 0.001). There was a significant decrease in
the number of NF-𝜅B positive cells in OVA-M (11.04 ± 0.86)
and OVA-D (8.06 ± 0.70) compared to OVA group (𝑃 <
0.001).There were no differences between OVA-M andOVA-
D groups.
Figure 6(b) shows the NF-𝜅B expression in airway walls.
We observed a significant increase in the number of NF-
𝜅B (positive cells/104 𝜇m2) in OVA group (26.20 ± 1.34)
compared to control (SAL group: 11.95 ± 0.96, 𝑃 < 0.05).
There was a significant decrease in the number of NF-𝜅B
positive cells in OVA-M (12.84 ± 1.09) and OVA-D (8.95 ±
0.78) compared to OVA group (𝑃 < 0.05). Nevertheless,
dexamethasone group (OVA-D) was significantly reduced
in comparison to montelukast group (OVA-M). There were
6 BioMed Research International
30
25
20
15
10
5
0
SAL OVA OVA-M OVA-D
di
st
al
 lu
ng
 p
ar
en
ch
ym
a
∗∗
∗∗
∗
Fi
br
on
ec
tin
 p
os
iti
ve
 ce
lls
/1
0
4
𝜇
m
2
(a)
ai
rw
ay
 w
al
l
50
40
SAL OVA OVA-M OVA-D
30
20
10
0
∗
Fi
br
on
ec
tin
 p
os
iti
ve
 ce
lls
/1
0
4
𝜇
m
2
(b)
Figure 5: (a) Mean and SEM values of fibronectin positive cells in distal lung of GP that previously inhaled with normal saline or ovalbumin,
and after the 4th inhalation, GP were treated with montelukast (OVA-M group) and dexamethasone (OVA-D group). ∗𝑃 < 0.001 compared
to the other groups. ∗∗𝑃 < 0.001 compared to SAL group. (b) Mean and SEM values of Fibronectin positive cells in airway wall of GP
that previously inhaled normal saline or ovalbumin, and after the 4th inhalation, GP were treated with montelukast (OVA-M group) and
dexamethasone (OVA-D group). ∗𝑃 < 0.001 compared to the other groups.
no differences between OVA-M and OVA-D groups when
compared to SAL group.
3.7. Representative Photomicrographs of Airway Walls.
Figure 7 shows representative photomicrographs of guinea
pigs airway wall samples. We observed a significant increase
in the number of eosinophils, eotaxin positive cells, RANTES
positive cells, IGF-I positive cells, fibronectin positive cells,
and NF-𝜅B positive cells in OVA group compared to control
(SAL group). There was a significant decrease in eosinophils,
eotaxin positive cells, RANTES positive cells, IGF-I positive
cells, fibronectin positive cells, and NK-𝜅B positive cells in
OVA-M and OVA-D compared to OVA group.
3.8. Representative Photomicrographs of Distal Lung
Parenchyma. Figure 8 presents representative photo-
micrographs of guinea pigs distal parenchyma samples. We
observed a significant increase in the number of eosinophils,
eotaxin positive cells, RANTES positive cells, IGF-I positive
cells, fibronectin positive cells, and NF-𝜅B positive cells in
OVA group compared to control (SAL group). There was
a significant decrease in eosinophils, eotaxin positive cells,
RANTES positive cells, IGF-I positive cells, fibronectin
positive cells, and NK-𝜅B positive cells in OVA-M and
OVA-D compared to OVA group.
It is important to mention that two more control groups
were performed: saline groups treated either with mon-
telukast (SAL-M) or dexamethasone (SAL-D). There were
no statistical significant differences among the three control
groups, so we showed only one of them.
4. Discussion
Although corticosteroids are highly recommended as a first
line therapy for asthma, it is important to highlight that
montelukast can have a consistent benefit in controlling
asthma symptoms and can be used as an alternative for those
patients who have difficulties using inhaled corticosteroids
(especially young children) or have some kind of intolerance
with dexamethasone therapy [33]. Furthermore, a reduced
adherence with inhalants for asthma compared to those
therapies which are orally administrated has been addressed
[34, 35].
To elucidate the role of antileukotrienes and corticos-
teroids in the control of changes in asthma remodeling, we
evaluated the effects of montelukast or dexamethasone treat-
ments on eosinophilic recruitment, including its activation by
detecting eotaxin and RANTES positive cells in airways and
lung parenchyma in guinea pigs (GP), with chronic allergic
lung inflammation. Furthermore, to better comprehend the
mechanisms involved in the remodeling process, we evalu-
ated IGF-I and fibronectin in distal lung parenchyma and
airway walls. Considering the importance of NF-𝜅B, one
of the most important transcriptional factors involved in
asthmatic responses, we also analyzed the expression of this
protein in both pulmonary compartments.
We initiated these treatments only one day after the
fourth inhalation, because in a previous study, using passive
cutaneous anaphylaxis technique (PCA) [10], we observed
an increase in specific immunoglobulin G1 (IgG1) homo-
cytotropic anaphylactic antibodies in GP that received four
inhalations with ovalbumin (at the end of the second week of
this protocol).
Dexamethasone is considered a very potent anti-in-
flammatory therapy available for asthma. Its effects are prob-
ably related to a broad anti-inflammatory actions, includ-
ing a decrease in airway infiltration of lymphocytes and
eosinophils [36]. However, it is important to emphasize that
one of the major challenges in using corticosteroids is related
with their side effects [37], corroborating the need for better
BioMed Research International 7
50
40
30
20
10
0
SAL OVA OVA-M OVA-D
∗
di
st
al
 lu
ng
 p
ar
en
ch
ym
a
N
F-
𝜅
B 
po
sit
iv
e c
el
ls/
1
0
4
𝜇
m
2
(a)
50
40
SAL OVA OVA-M OVA-D
30
20
10
0
N
F-
𝜅
B 
po
sit
iv
e c
el
ls/
1
0
4
𝜇
m
2
ai
rw
ay
 w
al
l
∗
∗∗
(b)
Figure 6: (a) Mean and SEM values of NF-𝜅B positive cells in distal lung of GP that previously inhaled normal saline or ovalbumin, and
after the 4th inhalation, GP were treated with montelukast (OVA-M group) and dexamethasone (OVA-D group). ∗𝑃 < 0.001 compared to
the other groups. (b) Mean and SEM values of NF-𝜅B positive cells in airway wall of GP that previously inhaled normal saline or ovalbumin,
and after the 4th inhalation, GP were treated with montelukast (OVA-M group) and dexamethasone (OVA-D group). ∗𝑃 < 0.05 compared
to the other groups. ∗∗𝑃 < 0.05 compared to OVA-D group.
treatments that can improve the quality of life of asthmatic
patients.
CysLTs play a major role in the pathophysiology of
asthma, activating and recruiting some inflammatory cells,
promoting airway remodeling, and increasing bronchial
hyperreactivity and vascular permeability [38, 39].
Antileukotrienes are a new class of anti-inflammatory
drugs, which includes, Zafirlukast, Montelukast, Pranlukast,
and Zileuton. Montelukast is known to be a highly selective,
pharmacological antagonist of type 1 cysteinyl leukotriene
receptors (CysLT
1
Rs) which can recognize the cysteinyl
leukotrienes (CysLTs) LTD
4
and LTC
4
/LTE
4
expressed on
some inflammatory cells such as basophils, neutrophils, and
lymphocytes and also on some structural cells such as fibrob-
lasts, myofibroblasts, smoothmuscle cells, and epithelial cells
[38].
Since montelukast acts as a potent antagonist of the
proinflammatory aspects of the CysLTs, it reduces asth-
matic inflammation and airway resistance and also prevents
bronchoconstriction, controlling asthma inflammation and
improving inflammatory and pulmonary responses [40, 41].
Many studies in patients with asthma demonstrated
a decrease in the number of eosinophils in the airways
after treatment with corticosteroids [42]. Corticosteroids
can cause the induction of eosinophils apoptosis by the
mechanism known as programmed cell death, acting as a
target therapy in asthmatic patients [43]. McMillan et al.
[21] showed in mice chronically exposed to ovalbumin that
chronic administration of budesonide was able to decrease
airway hyperreactivity, as well as leukocyte infiltration, and
decreased production of Th2 mediators such as interleukin 4
(IL-4), interleukin 12 (IL-12), and eotaxin-1.
Concerning eosinophil recruitment, we observed that
both treatments tested were efficient in reducing this infiltra-
tion in distal lung and in airway walls.
Not only cysteinyl leukotrienes can act as a chemotactic
for eosinophils, but also RANTES, eotaxin and eotaxin 2 are
chemotactic substances that are involved during eosinophilic
recruitment [44–46].
Eotaxin and RANTES are known as members of the
C-C family of chemokines. The most important character-
istic of the C-C chemokines is their facility to chemoat-
tract and activate inflammatory leucocytes, particularly lym-
phocytes, monocytes, eosinophils, and basophils, and also
some stromal cells such as endothelial and smooth muscle
cells [47]. Another effect of eotaxins is their ability to
cause immunoglobulin E(IgE)-independent degranulation of
basophils [48].
A family of receptors mediates the activities of C-C
chemokines; in general, any C-C chemokine can bind to sev-
eral C-C receptors. Eotaxin is exceptional and binds only to
the chemokine receptor type 3 (CCR3). Furthermore, eotaxin
can chemoattract and activate eosinophils specifically, while
RANTES are less specific to eosinophils, chemoattracting
and activating other inflammatory cells as monocytes and
lymphocytes [49].
Montelukast has mainly antieosinophil properties [50,
51]. This could be one of the possible explanations in
our study suggesting why montelukast showed a better
performance when compared to dexamethasone treatment
while reducing eotaxin positive cells in distal parenchyma.
Another possibility is that eotaxins are considered to bemore
specific than RANTES when activating eosinophils during
the inflammation process.
A huge number of cells expressing eotaxin mRNA and
protein in the bronchial mucosa area of atopic asthmatics
compared with controls have been demonstrated by Ying et
al. [52] and Mattoli et al. [53]. Furthermore, Ying et al. [52]
showed CCR3 expression on local infiltrating eosinophils.
These studies reinforce the theory that eotaxin, by the action
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Figure 7: Representative photomicrographs showing guinea pig airway wall samples obtained from controls ((a), (e), (i), (m), (q), and (u)),
OVA-exposed ((b), (f), (j), (n), (r), and (v)), OVA-exposed MK treated ((c), (g), (k), (o), (s), and (w)), and OVA-exposed D treated ((d), (h),
(l), (p), (t), and (x)) stained with LUNA ((a) to (d)—×1000) and immunohistochemistry for eotaxin detection ((e) to (h)—×1000), RANTES
detection ((i) to (l)—×1000), IGF-I detection ((m) to (p)—×1000), fibronectin detection ((q) to (t)—×1000), and NF-𝜅B detection ((u) to (x)).
Control groups show a scarce number of eosinophils, eotaxinpositive cells, RANTES positive cells, IGF-I positive cells, fibronectin positive
cells, andNF-𝜅B positive cells. In contrast, the airway wall of OVA-exposed animals shows intense eosinophilic infiltration (b), a large number
of eotaxin positive cells (f), RANTES positive inflammatory cells (j), IGF-I positive inflammatory cells (n), fibronectin positive inflammatory
cells (r), and NF-𝜅B positive inflammatory cells. Both treatments (MK and D) in ovalbumin-exposed animals reduced all these parameters.
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Figure 8: Representative photomicrographs of guinea pigs distal lung samples obtained from controls ((a), (e), (i), (m), (q), and (u)), OVA-
exposed ((b), (f), (j), (n), (r), and (v)), OVA-exposed MK treated ((c), (g), (k), (o), (s), and (w)), and OVA-exposed D treated ((d), (h), (l),
(p), (t), and (x)) stained with LUNA ((a) to (d)—×1000) and immunohistochemistry for eotaxin detection ((e) to (h)—×1000), RANTES
detection ((i) to (l)—×1000), IGF-I detection ((m) to (p)—×1000), fibronectin detection ((q) to (t)—×1000), and NF-𝜅B detection ((u) to (x)).
Control groups show a scarce number of eosinophils, eotaxin positive cells, RANTES positive cells, IGF-I positive cells, Fibronectin positive
cells and NF-𝜅B positive cells. In contrast, the distal lung parenchyma of OVA-exposed animals shows intense eosinophilic infiltration (b), a
large number of eotaxin positive cells (f), RANTES positive inflammatory cells (j), IGF-I positive inflammatory cells (n), fibronectin positive
inflammatory cells (r), and NF-𝜅B positive inflammatory cells. Both treatments (MK and D) in ovalbumin-exposed animals reduced all these
parameters.
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of binding only to CCR3, plays a role in the specific recruit-
ment of eosinophils to the asthmatic bronchial mucosa, a
phenomenon which in turn regulates asthma severity.
In many asthmatic patients, the addition of anti-
leukotriene can be a valuable approach for uncontrollable
asthma regardless of treatment with inhaled corticosteroid
despite the fact that little is known about its molecular
mechanism.
Wu et al. [54] studying to the effect of a 3-day course of
high-dose montelukast on mediators of airway inflammation
induced by a single allergen challenge in sensitized mice
showed that eotaxin protein and mRNA expression in the
lung remained unchanged.
Uguccioni et al. [55] using pranlukast (another anti-
leukotriene) in vitro, evaluated eosinophil transmigration
across human umbilical vein endothelial cells in response
to LTD4, eotaxin, RANTES, and platelet-activating fac-
tor (PAF). They showed that pranlukast did not modify
eosinophil transmigration in response to eotaxin, RANTES,
or PAF.
Nevertheless, in the present study, both treatments tested
were efficient in reducing eotaxin positive cells in distal lung
and in airway walls. Althoughmontelukast treatment showed
more efficiency in reducing eotaxin positive cells in distal
lung parenchyma compared to dexamethasone treatment,
both of them reduced these parameters in airway walls.
Some studies have shown the chemoattractant power
activity of RANTES for eosinophils in airway allergic
inflammation. Gonzalo et al. [56] showed that treatment
with methylated RANTES (a CCL5 antagonist) decreased
eosinophilia after antigen challenge by blocking the activa-
tion of RANTES and its binding to the receptor.
Regarding the evaluation of RANTES positive cells, we
noted that both treatments have shown effectiveness either
in distal lung parenchyma or in the airway wall contributing
to a better control of asthma.
Lung remodeling and chronic inflammation are impor-
tant characteristics of asthma. It has been shown that mod-
ulation of fibroblasts into myofibroblastic phenotype, with
addition of particular contractile aspects, indispensable for
connective tissue remodeling during the wound healing pro-
cess in asthmatics airways [57]. Nonetheless, the connection
between fibroblasts, myofibroblasts, and smooth muscle cells
needs to be better investigated [58].
Fibroblasts are responsible for producing a wide array of
extracellular matrix components like collagen, reticular and
elastic fibers, laminin, fibronectin, hyaluronic acid, glycopro-
teins, and proteoglycans amorphous extracellular substance
[59, 60]. Nam et al. [61] showed that primary bronchial
fibroblasts were susceptible to mechanical stimuli during
differentiation into myofibroblasts. Furthermore, they have
addressed that fibroblasts from asthmatics showed higher
potential for tissue fibrosis when compared to control group.
Myofibroblasts are known to be contractile cells with
biochemical and morphologic aspects that stay somewhere
between fibroblasts and smooth muscle cells [62, 63]. TGF-
𝛽 is the major regulator that promotes myofibroblast dif-
ferentiation through its capacity to accumulate intracellular
contractile proteins, fibronectin containing extra type III
domain A (EDAcFN), and collagen density [57].
Through inflammatory mesenchymal and epithelial cells,
amultimeric form of cellular fibronectin is produced, and it is
deposited in the fibrils of the extracellular matrix, containing
variable portions of the extra type III domain A and B (EDA
and EDB) sequences [64]. These domains are known to play
an important role in the contribution of EDAcFN to fibroblast
activation [65] and wound healing process [66].
Fibronectin matrix formation is a dynamic, cell-
dependent process that is tightly regulated. The loss of
this regulation promotes an increase in the deposition of
fibronectin and other extracellular matrix (ECM) molecules
in the subepithelial matrix in patients with asthma. A specific
site of fibronectin modulates cell contractility, collagen gel
contraction, and cell migration. Furthermore, the increased
or inappropriate exposure of this site in matrix fibronectin
may lead to abnormal tissue remodeling by enhancing
and/or prolonging cell contractility and by altering the rate
of reepithelialization. The development of new strategies to
control the extent and duration of the exposure of cells to
matrix-specific epitopes can supply a functional method to
structure normal tissue remodeling in asthma [6].
The cysteinyl leukotriene LTD4 causes a potentiation
of fibronectin-induced migration of human lung fibroblasts
[67], contributing to the airway remodeling process. Further-
more, Tokuriki et al. [68] observed that the leukotriene D
4
acts as a precipitating factor during the remodeling mediated
by endothelin-1, and antileukotrienes have a role in prevent-
ing aberrant extracellularmatrix degradation.An experimen-
tal mice model of asthma showed that the antileukotrienes
inhibit the process of airway remodeling, including the influx
of eosinophils into the lungs, eosinophil degranulation, the
release of Th2 cytokines, hyperplasia of mucous glands,
hypersecretion mucus, hyperplasia of smooth muscle cells,
collagen deposition, and pulmonary fibrosis [69].
In this study, we observed an increase in fibronectin
positive cells in chronic allergic lung inflammation model.
Both treatments tested were able to decrease the number of
fibronectin positive cells in distal lung parenchyma and in
distal airway walls.
Fibrosis and asthma are highly linked by the increased
deposition of extracellular matrix at specific places in the
airway wall. Growth factors may be considered during
asthma remodeling. Increased expression of TGF-𝛽 [70]
has been shown in lung fibrosis and plays an important
role in the excessive matrix deposition and also in cell
proliferation. IGF-I is known to be a highly potent mitogen
for fibroblasts and smooth muscle cells, acting on fibroblasts
as a progression factor pushing the cells from a G1 phase
to mitosis in the cell cycle, activating them to make the
collagen synthesis [71]. It is important to emphasize that
collagen deposition at the lamina reticularis contributes to
the remodeling process, an asthma characteristic, enhancing
the role that IGF-I can play as an important mediator of
inflammation and remodeling in asthmatic airways.
Muz et al. [72] showed that airway collagen deposi-
tion/fibrosis was reduced after montelukast treatment, sug-
gesting that cysteinyl-leukotrienes have an important role
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in collagen deposition/lung fibrosis. In addition, Henderson
Jr. et al. [73] showed that montelukast could significantly
reduce airway remodeling in a mouse model of chronic
asthma, addressing montelukast effect in some aspects of the
remodeling process.
Veraldi et al. [5] showed that insulin-like growth factor
binding protein-3 IGFBP-3 levels are increased in bron-
choalveolar lavage (BAL) fluid of asthmatic patients 48
hours after allergen challenge, suggesting that this is the
most important protein that IGF binds, developing airway
remodeling in asthma through this modulation. Considering
this, the creation of an IGFBP-3 antagonist could be a promise
therapeutic target for asthma treatment.
Rajah et al. [74] using cultured airway smooth muscle
cells addressed the synergism between IGF and inflammatory
agents such as leukotrieneD
4
and interleukin 1-beta, showing
that these agents induce the secretion of an IGFBP protease
which cleaves the IGFBPs secreted by airway smooth cells.
This event allows IGF to stimulate proliferation, emphasizing
that IGFBP proteases act as a critical element in asthma
and other diseases. Rajah et al. [75] also reported that
antimatrix metalloproteinase (MMP-1) acts as an IGFBP
protease induced by leukotrienes that plays an important role
in modulating IGF action in airway smooth muscle cells.
Our findings showed that the anti-leukotriene montelukast
reduced IGF levels in distal lung parenchyma and airway
walls in experimental models of chronic allergic inflamma-
tion.
Hoshino et al. [76] have investigated the effects of inhaled
corticosteroids in asthmatic patients. They observed a signif-
icant decrease in thickness of the subepithelial collagen and
also an important reduction in the number of fibroblasts and
the expression of IGF-I, suggesting that the decrease in colla-
gen thickness after the treatment with inhaled corticosteroid
could be a result of blocking the transcription of the IGF-I
gene. In our study, we observed a decrease in IGF with both
treatments. However, dexamethasone treatment was more
efficient in reducing IGF-I positive cells in distal parenchyma
when compared to montelukast treatment.
Corticosteroids are known to play an important role in
the therapy of a large number of diseases, especially diseases
of the gastrointestinal tract and liver [77]. Gayan-Ramirez
et al. [78] showed that corticosteroid treatment in rats was
highly linked with a reduction in IGF-I serum levels mainly
after triamcinolone treatment that resulted from a decrease
in IGF-I manifestation in the liver.
Our findings showed that dexamethasone was more effi-
cient when compared to montelukast treatment in reducing
the expression of IGF-I in distal lung parenchyma.This could
be explained since this growth factor is synthesized and
released by the liver and can be mediated by the action of
corticosteroids [79].
Further studies are needed to ascertain the molecular
mechanisms involving IGF-I and the current therapies.
NF-𝜅B is a transcription factor, and it plays an important
role in expression of lots of proinflammatory genes, which
leads to the synthesis of growth factors, adhesion molecules,
and chemokines [80].
Lin et al. [81] showed that total lung extracts from
brownNorway rats exhibit enhanced NF-𝜅B activity after the
ovalbumin (OVA) sensitization and challenge model. There
is also a relation between NF-𝜅B and nitric oxide (NO).
When inducible nitric oxide synthase (iNOS) is activated, it
generates a high concentration of NO through the activation
of some inducible nuclear factors, including the NF-𝜅B [82].
Our results showed a higher efficacy of corticosteroids
compared to montelukast treatment in reducing NF-𝜅B in
airway walls. This can be explained by the broad mecha-
nism that corticosteroids play, by switching off the expres-
sion of multiple genes, including adhesion molecules and
chemokines [83].
NF-𝜅B activity is highly regulated by its interaction with
I𝜅B proteins. One possible explanation to corticosteroids
higher efficacy in reducing NF-𝜅B is that they can be
involved in regulating the expression of I𝜅Bproteins. Another
possibility is that NF-𝜅B is regulated during the interaction
with other coactivators, such as transcriptional co-activator
proteins (CBP/p300), which are highly known to interact
with NF-𝜅B promoting transcription [83].
Arachidonate 5-lipoxygenase (ALOX5) is an enzyme that
synthetizes the cysteinyl leukotrienes LTC
4
, LTD
4
, LTE
4
,
and LTB
4
. ALOX5 inhibition can be associated with an
improvement in asthma outcome, and it is known that the
ALOX5 gene promoter has binding-sites for some transcrip-
tion factors, including NF-𝜅B. However, not all asthmatic
patientswill respond to antileukotrienes since thosewhohave
mutant alleles at the ALOX-5 should not have clinical benefits
[84]. This could be a possible explanation of the relative lack
of response by montelukast treatment in reducing NF-𝜅B in
airway walls.
Considerable attention has been given to the signaling
pathways related with the NF-𝜅B activation. These signaling
protein molecules can be, in the near future, a potential
therapeutic target to block NF-𝜅B activation, interrupting
the asthma process. Further studies are needed to better
understand how these molecules interact with each other
[85].
Despite the fact that there is current evidence of the
importance of these treatments on airways regarding the
control of main morphofunctional alterations present on
asthma, the present study enlightens that isolated treatment
with these drugs was chiefly capable of controlling also distal
lung parenchyma alterations.
It is worthy tomention that, in the present study, all of the
drugswere systemically administered, not through inhalation
that probably contributed to the efficacy of the treatment on
distal lung parenchyma.
Despite all the scientific and ethical care involved in the
insertion of a new formof treatment for any disease, only after
some time of use we can adequately characterize its efficacy’s
spectrum. This motivates the need for practical applications
that help people. In other words, translational medicine,
research that aims to move “from bench to bedside” or from
laboratory experiments through clinical trials to point-of-
care patient applications or dissemination to population-
based community interventions. Thus, this study used and
experimental model of chronic allergic inflammation to
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better understand the mechanisms involved in the patho-
physiology of asthma. We observed important results on the
relation of the available treatments for allergic diseases and
the immune response on the asthmatic patient. Our goal is a
continuous feedback loop to accelerate the translation of data
into knowledge from the basic sciences into the development
of new treatments, translating the findings from clinical trials
into everyday practice.
5. Conclusion
In this animal model, both corticosteroid and montelukast
treatments were effective in the control of the inflamma-
tory response in distal lung parenchyma and distal airway
walls. But it is noteworthy to emphasize the contribution
of montelukast in the resolution of some inflammatory
and remodeling aspects in this experimental model, mainly
in the control of distal lung parenchyma functional and
histopathological alterations.
In conclusion, asthma is a chronic disease and corti-
costeroids are considered to be a gold standard medical
therapy. However, since corticosteroids can have a wide
range of side effects, it is essential that studies of therapeutic
efficacy consider alternative treatments. Antileukotrienes are
an orally, safe administered, nonsteroidal therapy for treating
mild persistent asthma, especially in young children.They are
an option for the treatment of asthma, based on many of its
biological effects described above.
Therefore, our data contributes to a better understanding
of the inflammatory and remodeling processes in both
treatments in this experimental model of asthma and may
assist researchers to further studies based on their expected
outcomes.
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